<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005754</url>
  </required_header>
  <id_info>
    <org_study_id>Pro-2021</org_study_id>
    <nct_id>NCT05005754</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Cardiometabolic Health</brief_title>
  <official_title>An Interventional Study for the Beneficial Effects of Probiotics on Cardio-metabolic Health in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of&#xD;
      gut microbiota has been reported to play an important role in the pathogenesis of&#xD;
      atherosclerosis. Animal studies have demonstrated that administration of probiotics help&#xD;
      delay the progression of atherosclerosis through several mechanisms. This trial aims to&#xD;
      examine its protective effect in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of&#xD;
      gut microbiota has been reported to play an important role in the pathogenesis of&#xD;
      atherosclerosis. Animal studies have demonstrated that administration of probiotics help&#xD;
      delay the progression of atherosclerosis through several mechanisms such as reduction in&#xD;
      endotoxemia, and enhanced production of short-chain fatty acids.&#xD;
&#xD;
      However, whether administration of probiotics also has a protective effect in subjects with&#xD;
      metabolic syndrome (MetS), who are at high risk for developing atherosclerosis, remain&#xD;
      unknown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated slowing (FMS)</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>FMS is a simple test for endothelial functions measured by Vicorder. In patients whose endothelial function or flow-mediated vasodilation are compromised, the FMS is substantially reduced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbiota</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>Alterations of the composition of gut microbiota evaluated by metagenomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbial metabolites</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>alterations of microbial metabolites evaluated by High performance liquid chromatography-mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome Severity Z Score (MetZ score)</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>MetZ score is an weighted score of the five traditional components of Metabolic syndrome (waist, triglyceride, HDL cholesterol, SBP and fasting glucose). It's used to evaluate the severity of metabolic disorder, and a higher score indicates a more severe status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>alterations of blood lipids including total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol determined by automatic biochemical analyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>alterations of blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>from baseline to 12 weeks after intervention</time_frame>
    <description>alterations of HOMA-IR index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiometabolic Risk Factors</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are instructed to take one capsule of probiotics daily for a total of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are instructed to take one capsule of placebo daily for a total of 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Local residents aged between 30-60 years old;&#xD;
&#xD;
          -  Stable weight (&lt;5% weight change over last 3 months);&#xD;
&#xD;
          -  Central obesity defined as waist circumference ≥90 cm in males or ≥80 cm in females,&#xD;
             Plus any two of the following four conditions i) Elevated triglycerides: serum&#xD;
             triglycerides ≥150 mg/dL (1.7 mmol/L); ii) Reduced HDL cholesterol: serum HDL-c &lt;40&#xD;
             mg/dL (1.03 mmol/L) in males or &lt;50 mg/dL (1.29 mmol/L) in females; iii) Elevated&#xD;
             blood pressure: systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85&#xD;
             mmHg; iv) Elevated fasting plasma glucose: fasting plasma glucose ≥100 mg/dL (5.6&#xD;
             mmol/L)&#xD;
&#xD;
          -  Absence of any systemic, cardiovascular diseases, as well as infections within the&#xD;
             previous month;&#xD;
&#xD;
          -  Absence of any diet or medication that might interfere with metabolic homoeostasis and&#xD;
             gut microbiota, especially antibiotics and probiotics 4 weeks before recruitment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness or current evidence of acute or chronic inflammatory of infective&#xD;
             diseases;&#xD;
&#xD;
          -  Participation in regular diet program more than 2 times per week in the latest 3&#xD;
             months prior to recruitment;&#xD;
&#xD;
          -  Mental illness rendering them unable to understand the nature, scope, and possible&#xD;
             consequences of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min Xia, PhD</last_name>
    <phone>+86-20-87332433</phone>
    <email>xiamin@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nutrition and Food Hygiene</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Xia, PhD</last_name>
      <phone>+86 20 87332433</phone>
      <email>xiamin@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Min Xia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

